{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=luteinizing+hormone-releasing+factor",
    "query": {
      "intervention": "luteinizing hormone-releasing factor"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 428,
    "total_pages": 43,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=luteinizing+hormone-releasing+factor&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-26T02:21:11.227Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03565835",
      "title": "Abiraterone With Discontinuation of Gonadotropin-Releasing Hormone Analogues in Metastatic Prostate Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Prostatic Neoplasms"
      ],
      "interventions": [
        {
          "name": "Abiraterone Acetate",
          "type": "DRUG"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Montefiore Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 31,
      "start_date": "2018-06-13",
      "completion_date": "2021-11-17",
      "has_results": true,
      "last_update_posted_date": "2026-01-26",
      "last_synced_at": "2026-09-26T02:21:11.227Z",
      "location_count": 1,
      "location_summary": "The Bronx, New York",
      "locations": [
        {
          "city": "The Bronx",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03565835"
    },
    {
      "nct_id": "NCT00186121",
      "title": "Estradiol Suppression for the Treatment of Metastatic Breast Cancer in Premenopausal Women",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Anastrozole (Arimidex)",
          "type": "DRUG"
        },
        {
          "name": "Goserelin (Zoladex)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Stanford University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 70 Years · Female only"
      },
      "enrollment_count": 35,
      "start_date": "2000-10",
      "completion_date": "2013-06",
      "has_results": true,
      "last_update_posted_date": "2019-10-07",
      "last_synced_at": "2026-09-26T02:21:11.227Z",
      "location_count": 1,
      "location_summary": "Stanford, California",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00186121"
    },
    {
      "nct_id": "NCT03141671",
      "title": "Randomized Phase II Study of Salvage XRT + ADT +/- Abiraterone and Apalutamide for Rising PSA After RP (FORMULA-509)",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "GnRH",
          "type": "DRUG"
        },
        {
          "name": "Bicalutamide",
          "type": "DRUG"
        },
        {
          "name": "Salvage radiation",
          "type": "RADIATION"
        },
        {
          "name": "Abiraterone",
          "type": "DRUG"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        },
        {
          "name": "Apalutamide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "Dana-Farber Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "95 Years",
        "sex": "MALE",
        "summary": "18 Years to 95 Years · Male only"
      },
      "enrollment_count": 345,
      "start_date": "2017-11-24",
      "completion_date": "2025-12-31",
      "has_results": false,
      "last_update_posted_date": "2024-05-14",
      "last_synced_at": "2026-09-26T02:21:11.227Z",
      "location_count": 8,
      "location_summary": "San Diego, California • San Francisco, California • New Haven, Connecticut + 5 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03141671"
    },
    {
      "nct_id": "NCT01381016",
      "title": "Estrogen Sensitivity and Ovulatory Dysfunction in Obesity",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Obesity",
        "Infertility"
      ],
      "interventions": [
        {
          "name": "Estradiol",
          "type": "DRUG"
        },
        {
          "name": "Gonadotropin-releasing hormone (GnRH)",
          "type": "DRUG"
        },
        {
          "name": "Progesterone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Colorado, Denver",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "42 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 42 Years · Female only"
      },
      "enrollment_count": 30,
      "start_date": "2011-06",
      "completion_date": "2013-01",
      "has_results": true,
      "last_update_posted_date": "2015-04-20",
      "last_synced_at": "2026-09-26T02:21:11.227Z",
      "location_count": 1,
      "location_summary": "Aurora, Colorado",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01381016"
    },
    {
      "nct_id": "NCT00066690",
      "title": "Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Estrogen Receptor Positive Breast Cancer",
        "Progesterone Receptor Positive Tumor",
        "Recurrent Breast Carcinoma",
        "Stage IA Breast Cancer",
        "Stage IB Breast Cancer",
        "Stage IIA Breast Cancer",
        "Stage IIB Breast Cancer",
        "Stage IIIA Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Exemestane",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Oophorectomy",
          "type": "PROCEDURE"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        },
        {
          "name": "Radiation Therapy",
          "type": "RADIATION"
        },
        {
          "name": "Tamoxifen",
          "type": "DRUG"
        },
        {
          "name": "Triptorelin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER",
        "PROCEDURE",
        "RADIATION"
      ],
      "sponsor": "ETOP IBCSG Partners Foundation",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 65 Years · Female only"
      },
      "enrollment_count": 3066,
      "start_date": "2003-12-17",
      "completion_date": "2024-11-06",
      "has_results": true,
      "last_update_posted_date": "2026-08-26",
      "last_synced_at": "2026-09-26T02:21:11.227Z",
      "location_count": 480,
      "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Scottsdale, Arizona + 323 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Berkeley",
          "state": "California"
        },
        {
          "city": "Burlingame",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00066690"
    },
    {
      "nct_id": "NCT01669291",
      "title": "Effect of GnRH Antagonist vs Agonist Long on IVF Outcome, Peak Estradiol Level,and Duration of Stimulation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Fertility"
      ],
      "interventions": [
        {
          "name": "Bravelle and Menopur",
          "type": "DRUG"
        },
        {
          "name": "Agonist",
          "type": "DRUG"
        },
        {
          "name": "Antagonist",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Main Line Fertility Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "40 Years",
        "sex": "FEMALE",
        "summary": "21 Years to 40 Years · Female only"
      },
      "enrollment_count": 43,
      "start_date": "2012-07",
      "completion_date": "2014-05",
      "has_results": false,
      "last_update_posted_date": "2014-06-04",
      "last_synced_at": "2026-09-26T02:21:11.227Z",
      "location_count": 1,
      "location_summary": "Bryn Mawr, Pennsylvania",
      "locations": [
        {
          "city": "Bryn Mawr",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01669291"
    },
    {
      "nct_id": "NCT01234519",
      "title": "A Phase I/II Trial of AEZS-108 in Urothelial Cancer Patients Who Failed Platinum-chemotherapy",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Urothelial Carcinoma"
      ],
      "interventions": [
        {
          "name": "AEZS-108",
          "type": "DRUG"
        },
        {
          "name": "AEZS-108 at MTD",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AEterna Zentaris",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2010-11",
      "completion_date": "2014-11",
      "has_results": false,
      "last_update_posted_date": "2018-03-15",
      "last_synced_at": "2026-09-26T02:21:11.227Z",
      "location_count": 2,
      "location_summary": "Miami, Florida • Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01234519"
    },
    {
      "nct_id": "NCT00076440",
      "title": "Antigonadotropin-Leuprolide in Alzheimer's Disease Drug INvestigation (ALADDIN) VP 104 Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Alzheimer Disease"
      ],
      "interventions": [
        {
          "name": "Leuprolide acetate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Voyager Pharmaceutical Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "65 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "65 Years and older · Male only"
      },
      "enrollment_count": 90,
      "start_date": "2003-12",
      "completion_date": "2007-03",
      "has_results": false,
      "last_update_posted_date": "2009-12-11",
      "last_synced_at": "2026-09-26T02:21:11.227Z",
      "location_count": 13,
      "location_summary": "Fresno, California • Lafayette, California • Rancho Mirage, California + 10 more",
      "locations": [
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Lafayette",
          "state": "California"
        },
        {
          "city": "Rancho Mirage",
          "state": "California"
        },
        {
          "city": "Hamden",
          "state": "Connecticut"
        },
        {
          "city": "Boca Raton",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00076440"
    },
    {
      "nct_id": "NCT00003124",
      "title": "Hormone Therapy Plus Radiation Therapy in Treating Patients With Prostate Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "flutamide",
          "type": "DRUG"
        },
        {
          "name": "leuprolide acetate",
          "type": "DRUG"
        },
        {
          "name": "radiation therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "Herbert Irving Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "MALE",
        "summary": "Male only"
      },
      "enrollment_count": 105,
      "start_date": "1997-05",
      "completion_date": "2007-01",
      "has_results": false,
      "last_update_posted_date": "2014-01-06",
      "last_synced_at": "2026-09-26T02:21:11.227Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00003124"
    },
    {
      "nct_id": "NCT00006359",
      "title": "Androgen Suppression Plus Radiation Therapy in Treating Patients With Prostate Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "LHRH agonist",
          "type": "DRUG"
        },
        {
          "name": "antiandrogen",
          "type": "DRUG"
        },
        {
          "name": "radiation therapy",
          "type": "RADIATION"
        },
        {
          "name": "Brachytherapy boost",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "Alliance for Clinical Trials in Oncology",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "MALE",
        "summary": "18 Years to 120 Years · Male only"
      },
      "enrollment_count": 63,
      "start_date": "2000-09",
      "completion_date": "2012-03",
      "has_results": false,
      "last_update_posted_date": "2016-07-18",
      "last_synced_at": "2026-09-26T02:21:11.227Z",
      "location_count": 26,
      "location_summary": "Lewes, Delaware • Newark, Delaware • Wilmington, Delaware + 18 more",
      "locations": [
        {
          "city": "Lewes",
          "state": "Delaware"
        },
        {
          "city": "Newark",
          "state": "Delaware"
        },
        {
          "city": "Wilmington",
          "state": "Delaware"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Elkton MD",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00006359"
    }
  ]
}